EANM 2025 | Connecting Global Innovation, C Ray Accelerates Its Globalization Journey
C Ray at
EANM 2025
Barcelona, Spain, October 8, 2025 – The annual congress of the European Association of Nuclear Medicine (EANM) successfully concluded today in Barcelona. Marking the 40th anniversary of EANM's founding, this year's congress centered on cutting-edge advancements in Theranostics and cancer management. It attracted a record-breaking 9,431 participants (including 182 exhibitors, 10 of which were from China) and received 2,991 abstract submissions, underscoring the unprecedented dynamism and collaborative spirit within the global nuclear medicine community.
Seizing this pivotal international platform, C Ray made a remarkable appearance. The company not only presented robust clinical data, amplifying its "academic voice," but also vividly demonstrated the efficiency and value of its "One Site, One Stop" integrated CRDMO services. Through this engagement, C Ray reinforced its position as a rapidly growing partner of choice for global clients.
01
A Resonant Academic Voice
Two Studies Honored as Top-Rated Oral Presentations
At the congress, two studies on ²²⁵Ac-PSMA-CY313 in metastatic castration-resistant prostate cancer (mCRPC), supported by C Ray, were both selected as "Top Rated Oral Presentations." This dual recognition highlights the significant scientific interest and potential clinical value of the research C Ray is advancing.
Regarding this milestone achievement, the presenting speaker remarked:
"Presenting our findings on a globally renowned platform like EANM marks a significant milestone for C Ray," a company spokesperson stated. "There are currently very few teams worldwide capable of developing mature products based on alpha-emitting radionuclides. We have not only successfully developed ²²⁵Ac-PSMA-CY313 but have also generated robust clinical data from prospective studies. This fully demonstrates C Ray's accumulated expertise and sustained development capabilities in radiopharmaceutical R&D and clinical research."
02
Collaboration & Exchange
On-Site Engagement for Integrated CRDMO Solutions
During the congress, our team engaged in extensive discussions with clients and experts from around the globe regarding our full-spectrum, one-stop CRDMO service model for radiopharmaceuticals. The dialogue encompassed the entire industry chain, including early-stage PCC screening, CMC development, non-clinical studies, and cGMP-standard production.
Furthermore, C Ray actively explored with international partners the feasibility of shipping drug products from its Chengdu, China site to key regions such as the United States, Australia, and Europe, investigating potential global logistics solutions for radiopharmaceuticals.
This comprehensively demonstrated the unique advantages of C Ray's "One Site, One Stop" model:
On our integrated platform, traditionally fragmented R&D and production processes are efficiently consolidated, with all critical stages seamlessly connected within a single site. Through centralized resource management and optimized workflows, we significantly reduce clients' overall costs while enhancing delivery quality and efficiency—delivering a truly high-quality and effective solution.
To further foster communication and collaboration, C Ray, in partnership with Quark Medical, hosted a relaxed and engaging "Happy Hour" networking event during the congress. The gathering provided a wonderful opportunity for both longstanding and new partners to connect in a convivial atmosphere.
At the event, we also thoughtfully arranged a Hanfu (traditional Chinese attire) experience booth, where guests enthusiastically participated, trying on the elegant garments and taking commemorative photos. This immersive activity allowed attendees to appreciate the unique charm and aesthetic of Eastern culture in a memorable way.
While the congress has concluded, our pursuit of innovation continues. Empowered by the industry insights and recognition garnered at EANM, we remain committed to advancing the field of targeted radiopharmaceuticals. We look forward to reuniting with global experts, scholars, and industry peers in nuclear medicine to discuss cutting-edge advancements and jointly drive breakthroughs in radiopharmaceutical innovation.
We extend our sincere gratitude to all friends and partners who have followed and supported C Ray. Let's meet again at Vienna in 2026!
For more exciting highlights from our overseas activities, please scan the QR code below to follow our LinkedIn account.⬇️
Introduction to C Ray Therapeutics
C Ray Therapeutics is dedicated to delivering end-to-end solutions for innovative radiopharmaceuticals to clients around the world. Our services span process development, quality research, preclinical evaluation, IND Enabling, clinical supply, and commercial scale cGMP production, all backed by a reliable, robust logistics network. As of 2024, we have raised over USD 187 million in total funding.
As a dedicated CRDMO partner in radiopharmaceuticals, one of our core strengths is a stable, diversified supply of radionuclides. We are actively developing high-quality domestic sources while playing a leading role in integrating and fortifying the global supply chain—most notably securing access to challenging isotopes such as Ac-225. To date, we have supported the development of 16 Ac-225–labeled projects.
Committed to empowering the industry, C Ray Therapeutics is building an open, integrated “production–academia–research–application” platform. By pooling resources across the value chain and pioneering critical radiopharmaceutical technologies, we accelerate the clinical translation of integrated diagnostic & therapeutic solutions. Our goal is to drive innovation and industrial upgrading in the radiopharmaceutical sector, establishing ourselves as a global benchmark in the field.
